Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma

doi:10.4254/wjh.v14.i6.1190

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4473)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

159

WORD

HTML

1875

Figures (1-2)

249

Tables (1-3)

349

Sum=2678

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

231

Download

553

Sum=784

Publishing Process of This Article

Item

Count

Browse

298

Download

713

Sum=1011

Jun 27, 2022 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jun 27, 2022; 14(6): 1190-1199
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1190

Table 2 Treatment with direct-acting antivirals

Regimens	With HCC	Without HCC
DCV + ASV/SOF + LDV/SOF + Rib/GLE + PIB/others	13/24/6/6/4	45/103/35/58/20
SVR at 12 wk post-treatment, yes/no	52/1	250/8
AFP at EOT in ng/mL	7.64 ± 6.81^a	3.93 ± 3.99
AFP at SVR in ng/mL	6.60 ± 6.27^a	3.68 ± 2.64

^aP < 0.05 as compared between with HCC vs without HCC.

AFP: Alpha fetoprotein; ASV: Asunaprevir; EOT: End of treatment; DCV: Daclatasvir; GLE: Glecaprevir; HCC: Hepatocellular carcinoma; LDV: Ledipasvir; PIB: Pibrentasvir; Rib: Ribavirin; SOF: Sofosbuvir; SVR: Sustained viral response.

Citation: Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199
URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1190.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1190